Wealthfront Advisers LLC Vertex Pharmaceuticals Inc Transaction History

Wealthfront Advisers LLC

$29.7 Billion
Q2 2024

A detailed history of Wealthfront Advisers LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Wealthfront Advisers LLC holds 39,690 shares of VRTX stock, worth $18.7 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

39,690

Previous 40,397 1.75%

Holding current value

$18.7 Million

Previous $16.9 Million 10.17%

% of portfolio

0.06%

Previous 0.06%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$392.81 - $485.53 $277,716 - $343,269	-707 Reduced 1.75%	39,690 $18.6 Million
Q1 2024 Apr 19, 2024	SELL	$407.69 - $446.08 $107,222 - $117,319	-263 Reduced 0.65%	40,397 $16.9 Million
Q4 2023 Feb 09, 2024	SELL	$343.0 - $410.68 $207,515 - $248,461	-605 Reduced 1.47%	40,660 $16.5 Million
Q3 2023 Nov 01, 2023	SELL	$338.18 - $362.46 $120,392 - $129,035	-356 Reduced 0.86%	41,265 $14.3 Million
Q2 2023 Aug 07, 2023	BUY	$314.42 - $351.91 $547,719 - $613,027	1,742 Added 4.37%	41,621 $14.6 Million
Q1 2023 Apr 28, 2023	BUY	$283.23 - $323.1 $1.38 Million - $1.58 Million	4,883 Added 13.95%	39,879 $12.6 Million
Q4 2022 Feb 10, 2023	SELL	$285.76 - $321.48 $1.01 Million - $1.13 Million	-3,525 Reduced 9.15%	34,996 $10.1 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $1.26 Million - $1.4 Million	4,596 Added 13.55%	38,521 $11.2 Million
Q2 2022 Jul 20, 2022	BUY	$234.96 - $292.55 $4.36 Million - $5.43 Million	18,566 Added 120.88%	33,925 $9.56 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $1.82 Million - $2.15 Million	8,236 Added 115.63%	15,359 $4.01 Million
Q4 2021 Jan 21, 2022	BUY	$177.01 - $223.45 $252,239 - $318,416	1,425 Added 25.01%	7,123 $1.56 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $4,716 - $5,277	26 Added 0.46%	5,698 $1.03 Million
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $725,398 - $855,435	-3,869 Reduced 40.55%	5,672 $1.14 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $260,845 - $304,050	1,260 Added 15.22%	9,541 $2.05 Million
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $192,519 - $256,763	-930 Reduced 10.1%	8,281 $1.96 Million
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $1,278 - $1,515	-5 Reduced 0.05%	9,211 $2.51 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $209,696 - $275,094	930 Added 11.22%	9,216 $2.68 Million
Q1 2020 May 15, 2020	BUY	$199.77 - $247.81 $226,339 - $280,768	1,133 Added 15.84%	8,286 $1.97 Million
Q4 2019 Jan 21, 2020	BUY	$166.71 - $223.91 $99,525 - $133,674	597 Added 9.11%	7,153 $1.57 Million
Q3 2019 Oct 15, 2019	SELL	$166.23 - $187.09 $105,057 - $118,240	-632 Reduced 8.79%	6,556 $1.11 Million
Q2 2019 Aug 13, 2019	BUY	$164.61 - $190.37 $35,061 - $40,548	213 Added 3.05%	7,188 $1.32 Million
Q1 2019 May 13, 2019	BUY	$163.73 - $194.7 $22,103 - $26,284	135 Added 1.97%	6,975 $1.28 Million
Q4 2018 Feb 14, 2019	BUY	$151.91 - $192.21 $1.04 Million - $1.31 Million	6,840 New	6,840 $1.13 Million

Others Institutions Holding VRTX

# of Institutions

1,718

Shares Held

226M

Call Options Held

1.21M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $121B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wealthfront Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wealthfront Advisers LLC with notifications on news.

Account

Wealthfront Advisers LLC Vertex Pharmaceuticals Inc Transaction History